ProQR Therapeutics N.V. (PRQR)
Develops RNA editing treatments for genetic diseases like liver and nervous system disorders.
$1.76+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-15.4%
The outlook
ProQR Therapeutics is trading near the lower end of its 52-week range, with analyst consensus strongly favoring the stock. The average price target sits roughly 369% above the current price, though the stock's near-term trend against moving averages is mixed.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendMixed vs its moving averages
52-week range24% of the way from its 52-week low to high
Price targetAvg target +369% vs current price
Analyst price target
~12-month · 8 analysts$8.25average target+368.8% vs now
Now $1.76
Low $3.00High $12.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$248.4M
52-wk high
$3.10
52-wk low
$1.33
50-day avg
$1.64
200-day avg
$1.86
Trailing P/E
—